Meridian Bioscience has finalized its blockbuster sale to a pair of South Korean-based firms, a $1.53 billion acquisition that will end its long-time standing as a publicly traded firm.
Meridian Bioscience has finalized its blockbuster sale to a pair of South Korean-based firms, a $1.53 billion acquisition that will end its long-time standing as a publicly traded firm.
